SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 Q2 P&L / Income Statement

SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Revenue categories. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

401,251,000 US dollars

Total cost and expenses

387,960,000 US dollars

Operating income (loss)

13,291,000 US dollars

Other income (expense), net (calculated)

negative 15,040,000 US dollars

(Loss) income before income tax expense (benefit)

negative 1,749,000 US dollars

Income tax expense (benefit)

3,141,000 US dollars

Net (loss) income

negative 4,890,000 US dollars

Products, net

328,689,000 US dollars

Collaboration and other

72,562,000 US dollars

Cost of sales (excluding amortization of in-licensed rights)

149,385,000 US dollars

Research and development

91,258,000 US dollars

Selling, general and administrative

107,600,000 US dollars

Litigation contingency charge

39,000,000 US dollars

Amortization of in-licensed rights

717,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.